Figure 10.

Vaccination with SMA560 CRCL reduces tumor burden in syngeneic, tumor-bearing mice. Groups of VM/Dk mice (10 per group, initially) were inoculated subcutaneously with 100,000 SMA60 cells. Five days later, one group of mice received subcutaneous injections of CRCL vaccines (50 μg) derived from SMA560 tumor. Control mice received equal volumes of saline. Injections were given on the flank opposite the tumor, and tumor growth was monitored thereafter. Before day 34, two mice in the control group had died from their tumors, and their tumor volumes were censored from the averages and statistics shown here. avg vol, Average volume.